201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Losmapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Status changed from recruiting to completed.
- 28 May 2016 The trial was completed in Germany.